Physician profile
Nathan Zev Minkoff
NPI 1104211945
$131,207.26
in general payments reported to CMS, 2019-2025
28 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $675 · 2022: $333 · 2023: $853 · 2024: $50K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Travel and Lodging: $11K · Food and Beverage: $5,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,769.66 |
| Travel and Lodging | $10,946.17 |
| Food and Beverage | $5,483.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $93,648.58 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $34,422.15 | 2022-2025 | Dupixent |
| Wilson Cook Medical Incorporated | $514.37 | 2021 | |
| Qol Medical, LLC | $508.52 | 2022-2025 | Sucraid, Sucraid |
| Mirum Pharmaceuticals, INC. | $431.98 | 2022-2025 | Livmarli |
| Alcresta Therapeutics, INC. | $279.46 | 2024-2025 | Relizorb |
| Abbvie INC. | $234.05 | 2021-2025 | |
| Rhythm Pharmaceuticals, INC. | $199.17 | 2022-2025 | Imcivree, Imcivree |
| Albireo Pharma, INC. | $142.96 | 2023-2024 | Bylvay |
| Novo Nordisk INC | $137.84 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $125.00 | 2025 | Smoflipid |
| Cook Medical LLC | $124.87 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $48.36 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $45.52 | 2023-2024 | Gattex, Eohilia |
| Vertex Pharmaceuticals Incorporated | $41.16 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $39.49 | 2023 | |
| Olympus America INC. | $38.75 | 2025 | Single Use Electrosurgical Snare Sd-400 |
| Travere Therapeutics, INC. | $34.94 | 2022 | |
| Ironwood Pharmaceuticals, INC | $21.42 | 2024 | |
| Aimmune Therapeutics, INC. | $21.10 | 2024 | |
| Chiesi USA, INC. | $20.32 | 2022 | |
| Mylan Institutional INC. | $19.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.43 | 2023 | Cyltezo |
| Meridian Bioscience INC. | $19.10 | 2021 | |
| Janssen Biotech, INC. | $18.32 | 2024 | Stelara |
| Philips North America LLC | $18.14 | 2022 | |
| Erbe USA INC | $16.76 | 2024 | Vio3 Apc3 |
| Coloplast Corp | $15.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Minkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.